Currently, ongoing clinical trials are exploring the combination of CTLA-4 and PD-1/PD-L1 inhibitors to determine if it can produce better treatment outcomes in NSCLC patients (NCT03527251). Here, CTLA4 is linked to non-small cell lung carcinoma.